Questcor Pharmaceuticals (QCOR +4.5%) continues to recover from Wednesday's dramatic drop of...
Questcor Pharmaceuticals (QCOR +4.5%) continues to recover from Wednesday's dramatic drop of nearly 50%, as Roth Capital joins the chorus of analysts calling the reaction to the Aetna (AET) situation "overblown." QCOR's conference call yesterday "indicated that a highly-engaged and well-prepared reimbursement practice by QCOR has been successful and likely would continue as most cases are tightly sealed and more difficult for denial by insurers." the firm said in a note to clients.
From other sites
at Zacks.com (Tue, 8:47AM)
at Zacks.com (Mar 6, 2015)
at Nasdaq.com (Mar 3, 2015)
at Zacks.com (Feb 27, 2015)
at Nasdaq.com (Feb 12, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs